1-2 of 2
Dan Yao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Lijuan Chen, Yiwen Zhang, Dan Yao, Hui Li, Jordan M Schecter, Fan Yang, Huabin Sun, Sen Hong Zhuang, Da Xu, Tracy Luo, Xiaohu Fan, Ting Niu, Jie Jin, Sai-Juan Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 7542–7544.
https://doi.org/10.1182/blood-2022-159185
Published: 2022
Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Yuankai Shi, MD PhD, Yongping Song, MD PhD, Yan Qin, MD PhD, Qingyuan Zhang, MD, Xiaohong Han, MD, Xiaonan Hong, MD, Dong Wang, MD, Xiaofeng Zeng, MD PhD, Pei Hu, MD PhD, Shuiyu Zhao, Kaka Y. Hong, MSSB, Chaoming Ma, Jiancheng Cheng, Peng Ting, PhD, Kevin Li, MD, Weidong Jiang, PhD, Scott Liu, PhD, Eugene Liu, MD PhD, Xin Zhang, MD, Katherine Chai, PhD MsLaw, Dan Yao, PhD, Alvin Y. Luk, PhDMBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 2878.
https://doi.org/10.1182/blood-2019-130603
Published: 2019